Cyberonics Cuts Investment In VNS Depression Indication; Q4 Sales Up 64%
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics expects to scale-back its investment in developing a depression indication for its NeuroCybernetic Prosthesis vagus nerve stimulation system by 25% in fiscal 2003
You may also be interested in...
Cyberonics’ Sharpened Focus Buoys Stock 13% In May; OTC Index Off 2.6%
Cyberonics' revised NCP vagus nerve stimulation development plan for depression, combined with a sharper focus on epilepsy and fiscal fourth-quarter performance ahead of Wall Street expectations, led to a 12.5% stock gain in May
Cyberonics’ Sharpened Focus Buoys Stock 13% In May; OTC Index Off 2.6%
Cyberonics' revised NCP vagus nerve stimulation development plan for depression, combined with a sharper focus on epilepsy and fiscal fourth-quarter performance ahead of Wall Street expectations, led to a 12.5% stock gain in May
Cyberonics’ VNS Depression Indication Delayed Two Years By Trial Results
Cyberonics does not expect its annual losses to grow over the next three years due to the failure of a pivotal trial to demonstrate the efficacy of the NeuroCybernetic Prosthesis (NCP) vagus nerve stimulation (VNS) system in treating depression